| Principal Investigator |
NCCN Member Institution |
Title |
Publication |
| Tanios Bekaii-Saab, MD |
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute |
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas |
Cancer Chemotherapy and Pharmacology |
| Marc C. Chamberlain, MD |
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/University of Washington |
Salvage therapy with single agent bendamustine for recurrent glioblastoma |
Journal of Neuro-Oncology |
| Patrick Creaven, MD, PhD |
Roswell Park Cancer Institute |
A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer |
Cancer Chemotherapy and Pharmacology |
| Long H. Dang, MD, PhD |
University of Michigan Comprehensive Cancer Center |
Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment |
Molecular Cancer Therapeutics |
| Grace Dy, MD |
Roswell Park Cancer Institute |
Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer |
Journal of Thoracic Oncology |
| Manuel Hidalgo, MD, PhD |
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Assessment of Celecoxib Pharmacodynamics in Pancreatic Cancer |
Molecular Cancer Therapeutics |
| Renuka Iyer, MD |
Roswell Park Cancer Institute |
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study |
British Journal of Cancer |
| Milind Javle, MD |
Roswell Park Cancer Institute |
Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil |
Clinical Cancer Research |
| Andrew Ko, MD |
UCSF Helen Diller Family Comprehensive Cancer Center |
Optimizing the Administration of Fixed-Dose Rate Gemcitabine Plus Capecitabine Using an Alternating-week Schedule: A Dose Finding and Early Efficacy Study in Advanced Pancreatic and Biliary Carcinomas |
American Journal of Clinical Oncology |
| Razelle Kurzrock, MD |
The University of Texas MD Anderson Cancer Center |
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin-Bound Paclitaxel in Cancer Patients with Predominant Hepatic Metastases: Toxicity, Pharmacokinetics, and Activity |
Molecular Cancer Therapeutics |
| Daniel Laheru, MD |
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer |
Investigational New Drugs |
| Robert Maki, MD, PhD |
Memorial Sloan-Kettering Cancer Center |
Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas |
Journal of Clinical Oncology |
| James W. Mier, MD |
Beth Israel Deaconess Medical Center |
Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling |
Molecular Cancer Therapeutics |
| Stacy Moulder, MD, MSCI |
The University of Texas MD Anderson Cancer Center |
Phase 2 Study of Gemcitabine and Irinotecan in Metastatic Breast Cancer with Correlatives to Determine Topoisomerase I Localization as a predictor of response |
Cancer |
| Brian Rini, MD |
UCSF Helen Diller Family Comprehensive Cancer Center |
Maximal COX-2 Immunostaining Predicts Clinical Response to Celecoxib and Interferon Alpha Therapy in Metastatic Renal Cell Carcinoma |
Cancer |
| M. Wasif Saif, MD, MBBS |
University of Alabama at Birmingham Comprehensive Cancer Center |
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors |
Cancer Chemotherapy and Pharmacology |
| M. Wasif Saif, MD, MBBS |
Yale University School of Medicine |
Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies |
Phytomedicine |
| Manisha Shah, MD |
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute |
Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma |
The Journal of Clinical Endocrinology & Metabolism |
| Manisha Shah, MD |
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute |
High-dose celecoxib does not improve survival of patients with differentiated thyroid cancer |
Nature Clinical Practice Endocrinology & Metabolism |
| Charles L. Shapiro, MD |
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute |
Phase II Study of Sequentially Administered Low-dose Mitomycin-C (MMC) and Irinotecan (CPT-11) in Women with Metastatic Breast Cancer (MBC) |
Annals of Oncology |
| Charles L. Shapiro, MD |
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute |
Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer |
Clinical Breast Cancer |
| Przemyslaw Twardowski, MD |
City of Hope Comprehensive Cancer Center |
Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib |
Cancer Investigation |
| Sam S. Yoon, MD |
Massachusetts General Hospital |
Efficacy of Sunitinib and Radiotherapy in Genetically Engineered Mouse Model of Soft Tissue Sarcoma |
International Journal of Radiation Oncology* Biology*Physics |
E-mail
Print
Mark